Interestingly, inconsistent with the general results of EZH2 for triple-negative breast cancer, we found that patients with lower EZH2 expression had significantly shorter overall survival than those with higher EZH2 expression in TNBC patients (Figure 1b). Here, EZH2 is linked to triple-negative breast carcinoma.